YTX-7739

YTX-7739 is an orally active, brain-penetrant small molecule inhibitor of stearoyl-CoA desaturase (SCD), developed as a potential disease-modifying therapy for neurodegenerative diseases. Its primary mechanism is the inhibition of SCD, an enzyme involved in fatty acid metabolism and implicated in the pathological cascade leading to alpha-synuclein aggregation—a hallmark of Parkinson’s disease. By blocking SCD activity, YTX-7739 aims to modulate lipid pathways upstream of alpha-synuclein toxicity, potentially improving neuronal survival and motor function. Preclinical studies demonstrated that SCD inhibition by YTX-7739 reduced neurotoxicity and improved outcomes in models of Parkinson’s disease. The drug has shown favorable safety and pharmacokinetic profiles in Phase 1 trials with healthy volunteers and patients with mild-to-moderate Parkinson’s disease; it effectively crossed the blood-brain barrier and achieved target engagement as measured by reduction in fatty acid desaturation index (FA-DI). Development has also been explored for glioblastoma at the preclinical stage[1][2][3][4][5][6][7].